Objective. Premature atherosclerosis in patients with SLE is partially explained by traditional risk factors; therefore, we aimed to identify lupus-related risk factors for coronary artery calcifications.
Introduction
presence of carotid artery plaque or coronary artery calcifications, is detected in 3040% of lupus patients vs 916% of controls [4, 5] .
Lupus risk factors of premature atherosclerosis still need to be identified, since the excess burden persists after adjustment for traditional risk factors [6] . Disease-related characteristics, metabolic anomalies and inflammatory molecules have been proposed, without compelling evidence [4, 7, 810] .
Available information about premature atherosclerosis derives mostly from cross-sectional or retrospective studies, or cohorts followed during short periods, including prevalent patients, mostly whites, with a mean age of 4045 years, mean disease duration of 812 years and where potentially associated risk factors were assessed usually once [4, 5, 7, 10, 11] .
Whether the burden of atherosclerosis holds in young lupus patients within the early years of the disease is unknown. If it does, this would be an ideal population for identifying lupus-related risk factors because of the expected low prevalence of traditional risk factors and comorbidities. Also, their measurement at onset of lupus and over time should minimize any confounding effect on risk factor levels.
We hypothesized that the risk of premature atherosclerosis, evaluated as coronary artery calcifications, holds in young lupus patients since the early years of the disease, and that lupus-related factors, i.e. disease activity and inflammatory molecules analysed over time, would account for the risk not explained by traditional risk factors.
Methods

Study participants
We studied 139 ambulatory patients participating in a prospective cohort of lupus of recent onset at enrolment, and 100 healthy subjects, matched for age and sex. The study was approved by our hospital's institutional review board (Comite Institucional de Investigacion Biomedica en Humanos) and all subjects provided written informed consent.
Lupus cohort
In October 1999, an inception cohort of patients aged 516 years, who were within 12 months of accrual of 54 classification criteria for SLE [12] , was assembled as part of an international consortium for the study of atherosclerosis [13] . At entry, patients had a standardized medical history, physical examination and laboratory tests, including routine chemical analyses, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, lipoprotein(a) [Lp(a)] by cholesterol content, apolipoprotein B (ApoB), homocystein, high-sensitivity CRP (hs-CRP), serum complement (C 3 and C 4 ) and autoantibodies: ANA, anti-dsDNA, anti-Sm, anti-RNP/Sm, anti-SSA/SSB, aCL and anti-2-glycoprotein. Patients were considered to have a particular antibody if they tested positive according to our local laboratory cut-off values.
Every 36 months, patients were seen at the lupus clinic for medical care, and assessments of disease activity using the SLEDAI 2000 update (SLEDAI-2K) [14] and medications use and dose were carried out. Every year information was updated, including irreversible damage accrual using the SLICC damage index [15] , any comorbidities, traditional cardiovascular risk factors, and a blood sample was drawn. Clinical information was stored in a database containing demographic, anthropometric, lifestyle habits, medical family history, obstetric variables and lupus information. Two rheumatologists performed all assessments.
Coronary artery calcifications study
Between December 2007 and August 2008, all patients in the cohort were invited to participate in the coronary artery calcifications study. As controls, 100 healthy subjects age and sex matched to lupus patients were selected among 2503 health workers from our institute using a computergenerated randomization list. Exclusion criteria were pregnancy and history of MI or angina before SLE diagnosis or a dummy date for the controls. This criterion was intended to eliminate cardiovascular disease not associated with lupus.
At screening for calcifications, standardized information was acquired from all the participants by questionnaire, physical examination and laboratory tests. Additional information from lupus patients was retrieved from the database.
Assessment of cardiovascular risk factors included the presence of arterial hypertension (blood pressure 5140/90 mmHg or use of anti-hypertensive medications), diabetes mellitus, post-menopausal status (amenorrhoea of >12 months or bilateral oophorectomy), family history of MI (before 55 and 65 years of age in first-degree male and female relatives, respectively), smoking status, cholesterol levels after an overnight fast, BMI (weight in kilograms/square of height in metres), waist width, hs-CRP and homocystein levels; in addition, the Framingham 10-year risk factor profile was calculated [16] .
A nested analysis was conducted among all the lupus patients with coronary artery calcifications and a sample of lupus patients without calcifications (ratio 1 : 4), matched for age, sex and disease duration. In these patients, lipids and inflammatory molecules were measured in serum samples drawn at enrolment, mid-term follow-up and at the time of screening for calcifications. The analyses included total blood cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, Lp(a) and ApoB. picograms/millilitre. In addition, fasting levels of homocystein and hs-CRP were determined at enrolment and at screening.
CT
Coronary artery images were acquired in a 64-slice multidetector CT system (Somatom Sensation Cardiac 64, Siemens, Forcheim, Germany) following the recommended scan acquisition parameters [17] . The best diastolic cardiac phase was selected for reconstruction of the images, which were analysed in a dedicated workstation using calcium score software (Calcium Scoring, Siemens, Germany). The software employs an attenuation threshold of 130 Hounsfield units and a minimum of 3 contiguous pixels for identification of a calcified lesion. Each focus exceeding the minimum criteria was scored with the algorithm originally developed by Agatston et al. [18] . The total calcium score was determined by summing individual lesion scores from each of the left main, left anterior descending, left circumflex and right coronary arteries. One radiologist (E.K.-H.) read all CT scans blinded to the SLE or healthy control status.
Statistical analyses
The cumulative prevalence of coronary artery calcifications in lupus patients was plotted in a KaplanMeier curve by means of time-series analysis of cross-sectional data. Risk factors were summarized in terms of median (minimummaximum) or mean (S.D.) and absolute frequencies (%). Cumulative lupus activity during the entire period of follow-up was summarized as SLEDAI-2K areas under the curve AUCs and time-adjusted means [19] . Moderate/ severe activity was defined as a SLEDAI-2K score of 57. Univariate comparisons of cases and controls were conducted by means of the Student's t-test or MannWhitney U-test and chi-square or Fisher's exact test, as appropriate. Optimally, discriminator cut-off values were identified with receiver operating characteristic (ROC) analysis. Multiple regression and logistic regression models were run to account for potential confounders. As the age and disease activity were the two variables of primary interest, a two-sided P-value of 0.025 was considered as statistically significant (Bonferroni correction). 95% CI was determined when appropriate. The SPSS (SPSS Inc, Chicago, IL, USA, version 11.5) statistical package was used.
Results
Of 189 patients in the cohort, 50 were not studied: 27 were lost to follow-up, 6 refused to participate, 3 exclusion criterion (2 pregnancies and 1 angina) and 14 died; thus 139 patients participated. Demographic, anthropometric and lupus characteristics, co-morbidities, and cardiovascular risk factors at enrolment did not differ between participating and non-participating patients, except that hs-CRP levels were lower in participants [3.3 (3.5) vs 4.5 (3.7), P = 0.03, data not shown].
At enrolment into the cohort, participating lupus patients were 27.2 (9.1) years of age, with a mean lupus duration of 5.4 (3.8) months and mean SLEDAI-2K score of 6.9 (5.8). At screening for calcifications, mean age of patients and healthy subjects was similar [31.8 (8.8) vs 32.2 (9.8) years, P = 0.72], as well as most cardiovascular risk factors; however, patients had lower education, higher prevalence of hypertension, greater levels of homocystein and hs-CRP, wider waist and females were more often post-menopausal (Table 1) .
Coronary artery calcifications
Calcifications were detected in 10 (7.2%) of 139 patients and in 1 control [odds ratio (OR) 7.7, 95% CI 1.05, 336.3, P = 0.02]. The calcium score in nine lupus patients ranged between >0 and 20, and in the remaining patients it was 402; in the single positive control, a 51-year-old female, it was 239. Calcifications in lupus patients were detected since age 23 years, from 3 years of diagnosis, and the prevalence increased with age.
Coronary artery calcifications correlate in lupus patients
In comparison with patients without coronary artery calcifications, patients with calcifications were older, females were more often post-menopausal, had higher serum ApoB levels, used statins more often and the Framingham risk score at baseline and at screening was higher (P < 0.05) ( Table 2) . Nevertheless, most patients with coronary artery calcifications were at the lowest Framingham risk score (Fig. 1A) .
Lupus-related factors identified were older age at diagnosis (32 vs 25 years, P = 0.03), higher prevalence of IgG aCLs (60 vs 24%, P = 0.02), higher disease activity along the course of lupus (SLEDAI-2K AUC 19 vs13.3, P = 0.02; and SLEDAI-2K adjusted mean 7.2 vs 4.3, P = 0.04), longer period of moderate/severe activity (18.5 vs 3.0 months, P = 0.004), higher cumulative dose of prednisone (38.9 vs 19.4 g, P = 0.02) and CYC (20.5 vs 10.8 g, P = 0.04), and less use of anti-malarials ever (20 vs 65%, P = 0.006) ( Table 3 ). Persistent disease activity was observed among patients with coronary artery calcifications in comparison with patients without calcifications when it was analysed as paired data (Fig. 1B) . Also, the protective effect of anti-malarials persisted after controlling for disease activity (P = 0.008).
Due to the small number of patients with calcifications, and the skewed distribution of several variables, the following variables were dichotomized according to cut-off points selected using ROC curves analysis: age at enrolment 27.5 years, SLEDAI-2K AUC at screening 6.54 and length of lupus 3.2 years. Age at enrolment and SLEDAI-2K mean AUC at screening were selected because of statistically significant differences between the calcification and the non-calcification groups (P < 0.002 and P < 0.02, respectively). A 3.2-year length of lupus was the minimal disease duration to detect calcification, and this variable sorted the patients absolutely.
The results of the logistic regression analysis showed the following ORs: disease duration 1. 
Analyses of lipids and inflammatory molecules
Longitudinal analyses of lipids did not show a clear difference between patients with or without calcifications, although a trend for higher levels of triglycerides, total cholesterol, LDL cholesterol, ApoB and Lp(a) was observed among patients with calcifications. Neither was a difference observed in the levels of sCD40L, sVCAM, sICAM, MCP-1, IP-10, IL-6, IFN-g and hs-CRP; however, higher values of homocystein at enrolment were seen in patients with calcifications (Table 4) .
Discussion
Coronary artery calcifications were identified more frequently in young lupus patients than age-matched healthy controls. In lupus patients, calcifications were detected since the age of 23 years, from 3 years of diagnosis, and were associated with age, post-menopause status, ApoB levels and the Framingham risk score. Also, an association was observed with the following lupus-related factors: age at diagnosis, IgG aCLs, disease activity and cumulative dose of prednisone and CYC, but use of anti-malarials seemed to provide a protective effect. Estimating an adjusted OR for coronary artery calcifications between lupus patients and controls was unfeasible due to the small number of calcifications detected; however, the univariate logistic regression analysis of variables statistically different between them did not reach an association with coronary artery calcifications, except post-menopause status. Since this logistic model considered only females, and given that our calcification cases included a male, this analysis has gender limitations. Therefore, SLE is a true risk factor for coronary artery calcifications among both females and males, and among females, post-menopause status is a strong predictor of this outcome.
Our study supports an increased rate of atherosclerosis in lupus patients [35] . The prevalence and extent of Also, our results support the proposed interplay of traditional and lupus risk factors in the development of premature atherosclerosis [20] . Among the later, the association with age at diagnosis and aPLs has already been reported [4, 10, 13, 21] . However, a key finding in our study is the association of coronary artery calcifications with increased disease activity along the course of lupus, but most importantly, a longer period with moderate/severe activity. Although several studies failed to identify this association [4, 5, 7, 9, 10, 19] , probably due to design limitations, an association between lupus activity and angina/MI was identified in post-menopausal patients from the Toronto Lupus Clinic [22] , and a borderline association was observed with non-calcified plaque in patients from the Hopkins Lupus Cohort [23] . Disease activity is also a risk factor for premature atherosclerosis in RA, deriving in recommendations from the European League Against Rheumatism about the necessity for adequate control of inflammation to lower the cardiovascular risk [24] .
We also observed an association with cumulative doses of prednisone and CYC; although an independent association of atherosclerosis and cumulative dose of steroids is well established [25] , our study is underpowered to establish whether these results represent a true association or are confounded with disease activity.
The protective effect observed with anti-malarials on premature atherosclerosis has been reported in other studies [4, 26] . It may be explained by the anti-inflammatory, anti-hyperlipidaemic, anti-thrombotic and immunomodulatory properties of anti-malarials [27] . It also concurs with the favourable effects reported on flares, chronic damage and survival in general, but specifically with a reduction in cardiovascular mortality in lupus [2831] .
Longitudinal analyses of lipids showed non-significantly higher levels of triglycerides, total cholesterol, LDL cholesterol, ApoB and Lp(a) in patients with coronary artery The BMI is the weight in kilograms divided by the square of the height in metres.
calcifications. Similar results have been reported in cross-sectional studies of coronary artery calcifications in lupus [5, 7] . As there are no validated biomarkers of lupus activity to date, we tried to ponder representative inflammatory molecules that have been associated with disease activity. Thus, we included representatives of cytokine and chemokine families, endothelial activation and soluble surface molecules. However, sequential measurement of these potential serological biomarkers did not show any association. Diverse studies where cross-sectional assessment of these molecules was done have provided contradictory results [4, 8, 9] .
Recently, a pro-inflammatory HDL molecule associated with atherosclerosis in the general population [32] was found more frequently in patients with lupus and RA [33] and showed a strong association with atherosclerosis [26] . Also, antibodies to ApoAI and HDL that may affect their protective functions from atherosclerosis, and antibodies to malondialdehyde protein adducts and to 4-hydroxynonenal protein adducts, which are markers of oxidative stress, correlated with disease activity [34, 35] .
Our study would support the hypothesis that chronic inflammation favours ongoing oxidative damage resulting in increased levels of pro-inflammatory HDL and oxidized LDL causing premature atherosclerosis [26, 33] . The resulting changes could not be detected by measuring the plasma lipid levels and creates the need for new tests capable of detecting them in clinical practice. Also, our study supports the need for an effective suppression of disease activity and other modifiable risk factors for its prevention [20, 36] .
According to our results, screening for atherosclerosis in lupus should be focused in patients with disease duration of >3 years, plus age 527 years and/or sustained moderate to severe disease activity during the course of the disease. However, before considering this model as a formal recommendation for screening, it needs to be validated in other studies, especially since atherosclerosis results from the dynamic interplay of multiple factors, whose relevance for triggering vascular damage vary in different scenarios and times. In lupus patients with other characteristics, e.g. older age, longer disease duration and the relevance of each factor may change. Our study has several limitations. The low prevalence of coronary artery calcifications in our study population might limit the robustness of the results and conclusions, as well as the power to identify other factors potentially associated with calcifications; nevertheless, their relevance should be less than the weight imposed by the factors identified in the study. We did not study the presence of non-calcified coronary plaque, so our results may not apply to this lesion. Although in the general population the clinical relevance of a calcium score >0, including minimal coronary artery calcification, is well established [37] , in SLE, no studies have assessed the clinical utility of the calcium score at any value as a marker for increased risk of coronary heart disease. This is a single-centre study with limited ethnic variation; since the prevalence and extent of coronary artery calcifications varies across ethnic groups [38] , one must be cautious about extrapolating these results to all lupus patients. This study analyses longitudinally the association of traditional and lupus risk factors with coronary artery calcifications in an inception cohort of young patients within the early years of the disease. The mild extension of coronary artery calcifications reflects the early stages of atherosclerosis in the study population. The prevalence of traditional risk factors and disease-related comorbidities at enrolment was low; therefore, any confounding effect of these variables on the study of lupus risk factors for atherosclerosis should be minimal.
In conclusion, lupus patients are at an increased risk for developing coronary artery calcifications beginning at a young age and within the early years of the disease. High levels of disease activity along the course of lupus, older age at lupus diagnosis, presence of IgG aCLs and higher cumulative doses of prednisone and CYC contribute to the increased rate not explained by traditional risk factors. Effective control of disease activity, including the 
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Coronary artery calcifications in SLE use of anti-malarials, and modifiable traditional risk factors are critical to decrease the burden of premature atherosclerosis in SLE.
Rheumatology key messages
. Disease activity was identified as a novel lupus risk factor for coronary artery calcification. . Coronary artery calcifications were detected from the age of 23 years and from 3 years of lupus diagnosis. . Lipids, chemokines and adhesion molecules did not show differences in SLE patients with and without coronary artery calcification.
